Purpose: Epidermal growth factor receptor (EGFR) mutation status is important in treatment stratification of stage IV lung adenocarcinoma. We evaluated the relationship between the SUV max measured on PET/CT and EGFR mutations and the value of SUV max in predicting EGFR mutations. Patients and Methods: Seventy-one stage IV lung adenocarcinoma patients with verified EGFR mutations (48 EGFR mutant, 23 EGFR wild-type) having pretreatment PET/CT were retrospectively reviewed. SUV max values of the primary tumors (n = 71), nodal (n = 246), and distant metastases (n = 618) were compared between EGFR-mutant and EGFR wild-type adenocarcinoma by Mann-Whitney U test. The receiver operating characteristics curve and logistic regression were performed for factors, SUV max , age, sex, and smoking status. The significant predictors were assessed individually and in combination in discriminating EGFR mutation status. Statistical significance was assumed at P < 0.05 Results: The metastases in EGFR-mutant adenocarcinoma had lower SUV max than EGFR wild-type adenocarcinoma (nodal SUV max 3.4 vs 5.5, distant metastasis SUV max 3.4 vs 4.7, respectively; both P < 0.001). No statistical significant difference was observed in the primary tumors SUV max between the 2 groups (SUV max 7.4 vs 8.1, P = 0.311). A receiver operating characteristics-derived SUV max less than or equal to 7.2 in metastasis could separate EGFR-mutant from EGFR wild-type adenocarcinoma (area under the curve, 0.71-0.74; P < 0.05). SUV max was a significant independent predictor, and when combined with age, sex, and smoking status, it is highly predictive of EGFR mutation status (area under the curve, 0.90). Conclusions: Low SUV max in the metastasis favors the presence of EGFR mutations in stage IV lung adenocarcinoma, and SUV max is an independent predictor of EGFR mutations.
T yrosine kinase inhibitors (TKIs) have revolutionized the treatment of stage IV non-small cell lung cancer (NSCLC), especially in adenocarcinoma. The drug efficacy is dependent on the presence of epidermal growth factor receptor (EGFR) mutations that confer favorable response to TKIs. Although demographic characteristics such as age, sex, and smoking status were correlated factors with the presence of EGFR mutations, they were insufficiently sensitive to select individual for TKI therapy. Hence, the current recommendation remains in prioritizing EGFR mutation testing over other molecular predictive tests in all advanced stage lung adenocarcinoma. 1 Obtaining sufficient tumor material of good quality to allow for EGFR mutations testing remains challenging in advanced disease when the primary tumor is not resectable. 2 18 F-FDG PET/CT forms an essential staging tool for NSCLC. The glucose metabolism has been found to be associated with disease aggressiveness and cell proliferation. 3 Given that EGFR signaling transduction pathway is responsible for cell survival and proliferation, 4 previous studies have explored the relationship between the metabolic uptake and EGFR mutations. These studies showed correlations of opposite trends between pretreatment SUV max of the primary tumor and the presence of EGFR mutations, and one reported no correlation. [5] [6] [7] [8] [9] There was significant design heterogeneity among these studies, which included patients with different stages of disease and of various histological subtypes, thus difficult to draw conclusive results from these studies.
Herein, we aim to evaluate the metabolic signatures of the primary tumors and metastases in a Chinese cohort of stage IV lung adenocarcinoma in association to their EGFR mutation status and the value of SUV max in predicting EGFR mutations.
PATIENTS AND METHODS

Patients
Epidermal growth factor receptor mutations testing started at our hospital in 2009. We retrospectively identified all newly diagnosed therapy-naive patients with NSCLC who underwent staging PET/CT from January 2009 to January 2014. Inclusion criteria were (a) patients with histological confirmation of adenocarcinoma, (b) stage IV (both M1a and M1b) disease demonstrated either by PET/CT or proven by histology, and (c) EGFR mutation status determined. Staging was based on the new seventh revised edition for lung cancer staging by the International Staging Committee of the International Association of the Study of Lung Cancer. 10 The study was approved by the institutional review board, and the need for written informed consent was waived.
Eighty-nine stage IV NSCLC patients were identified, but EGFR mutation status was not verified in 17 of them due to insufficient tissue material. One PET/CT was excluded due to technical error that prevented retrospective quantitative analysis. Thus, the study population comprised 71 patients. The patients' demographics characteristics (age, sex, and smoking history) were collected. Nonsmokers were defined as those who never smoked or smoked less than 100 cigarettes in their lifetime, whereas patients who gave up smoking more than 1 year at the time of diagnosis were considered ex-smokers. The rest were categorized as current smokers. 5 
EGFR Mutation Status
Epidermal growth factor receptor mutations were tested on genomic DNA from frozen tumor tissues using Sanger sequencing of exons 18 to 21 or DNA extracted from formalin-fixed, paraffinembedded tumors using allele-specific polymerase chain reaction (PCR) (amplification refractory mutation system) (EGFR RGQ PCR Kit, Qiagen) according to previously described protocols. 11, 12 Tumors harboring EGFR mutations on these exons were labeled as EGFR mutant, and those without were labeled as EGFR wild-type.
PET/CT Acquisition and Analysis
PET/CT examinations were performed using dedicated PET/CT scanner (Discovery VCT, 64-multislice CT; GE Healthcare Bio-Sciences Corp, Piscataway, NJ). Patients were required to fast 6 hours before the examination, and the serum glucose level was maintained below 180 mg/dL before 370 MBq 18 F-FDG injection. An hour after 18 F-FDG injection, either a low-dose CT (FOV, 50 cm; pixel size, 3.91 mm; 0.5 second per CT rotation, pitch 0.984:1; 2.5-mm intervals; 120 kVp; 80-200 mA) or contrast-enhanced CT (same parameters but with 200-400 mA, 1.5 mL/kg IV contrast at a rate of 2.0 mL/s) was performed for anatomical correlation and attenuation correction, covering from skull base to the upper thighs. This was followed by PET emission scan, taking approximately 3 to 4 minutes per bed position and 5 to 6 bed positions per patient. PET images were reconstructed using 14 subsets and 2 iterations based on an ordered subset expectation maximization iterative algorithm.
All the examinations were retrospectively reviewed on dedicated ADW4.3 workstation (GE Healthcare, Milwaukee, Wis). Reviewers were blinded to the EGFR mutations at the time of review. Volume of interest was placed to encompass the entire primary tumor, lymph node, or metastasis, but carefully excluding tissue outside of the measured lesion by W.S.Q. and X.Y. to derive the SUV max . Radiologist E.Y.P.L. (with 3 years experience in PET/CT with special interest in thoracic imaging) subsequently verified all the lesions and volume of interest contoured. Metastatic lymph nodes were defined as lymph nodes with increased metabolic activity compared with background mediastinal blood pool based on visual qualitative analysis. Only lesions with the longest axis equal or more than 1.0 cm were included in the analysis to avoid partial volume effect. The SUV max was corrected based on lean body mass. In the presence of multiple metastatic lesions, 1 lymph node and 1 distant metastasis with the highest SUV max in each patient were selected for subgroup analyses. The lesions that were not biopsied were verified by follow-up imaging by either PET/CT or CT based on European Organization for Research and Treatment of Cancer and response evaluation criteria in solid tumors 1.1 criteria, respectively. 13, 14 Tumors that responded in concordant fashion as the overall disease in the form of complete response, partial response, stable disease, or disease progression were considered true-positive tumors, whereas tumors that responded different from the overall disease were considered false-positive tumors and would be excluded from analysis.
Statistics
Descriptive statistics were used for demographic data. Median value was expressed with ranges. Nonparametric Mann-Whitney U test was used to compare the difference in SUV max between EGFR-mutant and EGFR wild-type adenocarcinoma. Receiver operating characteristics (ROC) curve was constructed to derive the optimal cutoff value for SUV max in predicting EGFR mutation status. Demographic features (age, sex, smoking status) and SUV max with P < 0.05 in the univariate analysis were further analyzed by multivariate logistic regression to identify significant predictors for EGFR mutations. The SUV max was dichotomized by the ROC-derived cutoff value, and age was treated as continuous variable for both univariate and multivariate analyses. The ROC curves were constructed for individual 
RESULTS
Patients and Disease Characteristics
The median age of the study population was 65 years (range, 35-85 years). The median age of patients with EGFR-mutant adenocarcinoma (median, 70 years; range, 41-85 years) was higher than patients with EGFR wild-type adenocarcinoma (median, 57 years; range, 35-79 years) (P < 0.001). Further clinical characteristics were tabulated in Table 1 . The follow-up PET/CT or CT was performed at a median of 9.2 months (1.1-44.8 months). Five patients had shorter follow-up period of less than 3 months due to rapid disease progression given that our study cohort was stage IV adenocarcinoma with poor prognosis.
There were 48 patients with EGFR-mutant adenocarcinoma (with 4 patients having double EGFR mutations, Table 1 ) and 23 patients with EGFR wild-type adenocarcinoma (Figs. 1A, B ). Fortyeight patients (30 EGFR mutant and 18 EGFR wild-type) had nodal metastases with 246 metastatic lymph nodes evaluated. There were 618 distant metastases evaluated in 68 patients (45 EGFR mutant and 23 EGFR wild-type). Three patients had their brain metastases resected at the time of initial diagnosis of underlying NSCLC before staging PET/CT, therefore not evaluated. 18 
F-FDG Avidity of Tumors
There was no difference in the SUV max between the EGFRmutant and EGFR wild-type primary tumors (P = 0.311) (Fig. 2 , Table 2 ).
The SUV max of the EGFR-mutant lymph nodes was lower than EGFR wild-type adenocarcinoma (P < 0.001) ( Table 2 ). In subgroup analysis based on the highest nodal SUV max , the metabolic uptake remained significantly lower in the EGFR-mutant lymph nodes, SUV max of 3.5 (1.1-10.5), than EGFR wild-type lymph nodes, SUV max of 7.1 (2.4-19.1) (P = 0.005, Fig. 3A) .
The EGFR-mutant distant metastases had lower 18 F-FDG avidity (P < 0.001) ( Table 2 ). The SUV max of the most avid distant metastasis was lower in EGFR-mutant adenocarcinoma, SUV max of 5.8 (2.6-16.6), than EGFR wild-type metastasis, SUV max of 8.4 (3.0-18.1) (P = 0.006, Fig. 3B ).
ROC Curve Analysis Based on the Most
F-FDG-Avid Metastases
When attempting to optimize the sensitivity and maintaining a high specificity (>80%), SUV max less than or equal to 7.2 in both nodal and distant metastases could predict EGFR-mutant status. In lymph node categorization, 73% accuracy, 50% sensitivity, 87% specificity, 69% positive predictive value (PPV), 74% negative predictive value (NPV), area under the curve (AUC) of 0.74, and P = 0.005 were achieved; whereas in distant metastasis, the diagnostic characteristics were 72% accuracy, 57% sensitivity, 80% specificity, 59% PPV, 78% NPV, AUC of 0.71, and P = 0.006 ( Fig. 4 ).
Prediction of EGFR Mutation Status
The SUV max was dichotomized at SUV max of 7.2. In the univariate analysis, all factors tested (age, sex, smoking status, and SUV max ) were significantly correlated with EGFR mutation status (all P < 0.001). Subsequent multivariate logistic regression analysis demonstrated that all factors were significant predictors (all P < 0.001). The ROC curves analysis showed that each individual factor could predict EGFR mutation status with AUC ranging from 0.58 to 0.74. When FIGURE 2. Box plot of SUV max of primary tumors of EGFR-mutant and EGFR wild-type adenocarcinoma. There was no statistical significant difference in the SUV max of the primary tumors between EGFR-mutant (n = 48) and EGFR wild-type (n = 23) adenocarcinoma (P = 0.311). The boxes represent the 25th to 75th percentiles of the SUV max , and the crossbars denote the minimum and maximum values that were not outliers. The circle represents the mild outlier. (Fig. 5 ). 15, 16 
DISCUSSION
In this study, we demonstrated that the metastases, but not the primary tumor, from stage IV EGFR-mutant adenocarcinoma had significantly lower SUV max than EGFR wild-type adenocarcinoma and that SUV max was a significant independent predictor for EGFR mutations. When SUV max was combined with easily accessible demographic parameters, namely, age, sex, and smoking status, these were highly predictive of EGFR mutations with an AUC of 0.90. 15, 16 The EGFR mutation status is important in selecting NSCLC for TKI therapy. The clinical challenge remains with obtaining adequate tumor tissue of good quality, often from small samples acquired from bronchoscopic fine needle aspiration or core needle biopsies, for EGFR mutation analysis. Even with sensitive PCR approaches, insufficient DNA extraction from these small samples can result in artifacts that preclude confident interpretation, 17 as shown in 19% of our patients whom could not have their EGFR status verified and had to be excluded from the study cohort. This is often the limiting step in initiation of personalized treatment with TKIs.
The low SUV max in EGFR-mutant adenocarcinoma in our study may seem counterintuitive, given the role of EGFR in modulating cell survival. We propose that the cellular metabolism of the metastasis may have been altered after a series of complex cell biological events, FIGURE 3. Box plots of SUV max of metastases of EGFR-mutant and EGFR wild-type adenocarcinoma. A, The highest nodal SUV max from each patient in EGFR-mutant (n = 30) and EGFR wild-type adenocarcinoma (n = 18) was selected, and the difference was statistically significant (P = 0.005). B, The distant metastasis with highest SUV max from each patient in EGFR-mutant (n = 45) and EGFR wild-type adenocarcinoma (n = 23) was selected, and the difference was statistically significant (P = 0.006). The boxes represent the 25th to 75th percentiles of the SUV max , and the crossbars denote the minimum and maximum values that were not outliers. The circle represents the mild outlier, and the asterisk is the extreme outlier. . ROC curves of nodal and metastasis SUV max in predicting EGFR mutations. An SUV max less than or equal to 7.2 would predict EGFR mutations with high specificity. A, In nodal metastasis, accuracy was 73%, AUC was 0.74, and P = 0.005. B, In distant metastasis, accuracy was 72%, AUC was 0.71, and P = 0.006.
forming the invasion metastasis cascade. 18 It is plausible that the metabolic phenotype of EGFR-mutant primary tumor may differ from that of metastases. This biological adaptation supports our results in that the nodal and distant metastases from EGFR-mutant adenocarcinoma had lower SUV max but not the primary tumor. The lower metabolic uptake in EGFR-mutant adenocarcinoma could be related to the lower proportion of GLUT-1 overexpression in mutant-EGFR adenocarcinoma, 23% compared with 58% in EGFR wildtype adenocarcinoma. 19 Our study cohort was made up of all stage IV lung adenocarcinoma when compared with others published studies that included various stages and different histological subtypes of NSCLC (Table 3) . [5] [6] [7] [8] [9] The inclusion of different histological subtypes is likely going to impact upon the semiquantification of SUV max because squamous cell carcinoma is known to be more FDG avid than adenocarcinoma. 20 Some studies concentrated in analyzing the primary tumors but not the metastases, therefore potentially masking the different metabolic phenotypes expressed by the EGFR-mutant and EGFR wild-type metastases. 6, 9 Huang et al 5 drew different conclusion from ours and suggested that SUV max greater than 9.5 was more likely to harbor EGFR mutations in 77 patients. The discrepancy maybe related to the evaluation protocol that only included SUV max from the primary tumors and mediastinal nodal metastases but not distant metastases. Furthermore, the number of metastases per patient may have also affected the results. Higher SUV max in NSCLC with EGFR overexpression was observed in stage I resected primary tumors, but the results could be again confounded by high proportion (24.3%) of squamous cell origin in the cohort. 9 Despite statistical significant difference in the SUV max between the 2 groups, substantial overlap was observed in the lower ranges of SUV max of the metastases (Figs. 3A, B) , and tissue molecular confirmation should be performed whenever possible. In our study, identifying the EGFR mutation status was not feasible in 19% of the identified cases, indicating the clinical challenge in determining EGFR based on tissue molecular testing. Thus, SUV max maybe a useful adjunct to demographic features in predicting EGFR mutations.
This was a retrospective study that may introduce selection bias, likely explaining a high proportion of EGFR-mutant adenocarcinoma (68%) in our cohort. Our findings may be less applicable to populations that have lower incidence of EGFR mutation. The study only evaluated stage IV lung adenocarcinoma and would require further validation of our results in less advanced stage NSCLC. As clinically impractical and unethical, not all lesions were biopsied and analyzed individually for EGFR mutation status; this may introduce bias in the molecular analysis given disease heterogeneity, and validation through follow-up imaging could be imprecise. Thus, we could have included inflammatory and reactive lymph nodes.
CONCLUSIONS
In conclusion, the metastases of EGFR-mutant stage IV adenocarcinoma have lower metabolic phenotype compared with EGFR wild-type metastases, and SUV max is a significant independent predictor of EGFR mutations. N, total number; n, number in subgroups; ADC, adenocarcinoma; LN, lymph node; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
